AML represents a disease that develops from the uncontrolled growth and survival of undifferentiated leukemia stem cells. These stem cells are particularly dependent for survival upon the MCL-1 ...

The AACR poster presentation will provide an update on the data in AML patients most recently presented at the American Society of Hematology (ASH) Annual Meeting 2024 showing that ICT01 administered ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

and cell death. Abnormalities in tyrosine kinases are common in AML, and constitute an attractive therapeutic target. An example is given by the balanced chromosomal translocations (TEL-Abl ...

Increased mixed chimerism, as detected by AlloHeme, could predict post-transplant relapse “with a high degree of accuracy,” said Monzr M. Al Malki, MD.